Cost-effectiveness model of renal cell carcinoma (RCC) surveillance in hereditary leiomyomatosis and renal cell carcinoma (HLRCC).
Alexander J ThompsonYousef M AlwanVijay A C RamaniDafydd Gareth EvansEamonn R MaherEmma Roisin WoodwardPublished in: Journal of medical genetics (2022)
Annual CERMRI in HLRCC is cost-effective across age groups modelled.
Keyphrases